Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway
Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and glutamatergic pathways play key roles in the causes of OCD....
Gespeichert in:
| Veröffentlicht in: | Molecular psychiatry 2022-01, Vol.27 (1), p.230-248 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 248 |
|---|---|
| container_issue | 1 |
| container_start_page | 230 |
| container_title | Molecular psychiatry |
| container_volume | 27 |
| creator | Vallée, Alexandre Lecarpentier, Yves Vallée, Jean-Noël |
| description | Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and glutamatergic pathways play key roles in the causes of OCD. However, first-line therapies include cognitive-behavioral therapy but only 40% of the patients respond to this first-line therapy. Research for new treatment is mandatory. This review focuses on the potential effects of cannabidiol (CBD), as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which CBD provides its benefit properties. CBD medication downregulates GSK-3β, the main inhibitor of the WNT/β-catenin pathway. The activation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway and circadian rhythms dysregulation in OCD. Future prospective clinical trials could focus on CBD and its different and multiple interactions in OCD. |
| doi_str_mv | 10.1038/s41380-021-01086-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2644217906</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2644217906</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-ba9df86e301b6906acde5696cb6ff0506accb14b5c58b0496f95592a63d64a543</originalsourceid><addsrcrecordid>eNp9kE1OwzAQhS0EolC4AAtkibWpHf8kWaKKP6kCFkUsLdtx2lRpHOwU1GtxEM6EQwrsWM1o5ntvNA-AM4IvCabZJDBCM4xwQhAmOBOI7IEjwlKBOE-z_dhTniNGMjYCxyGsMO6X_BCMKM1omoj8CCyfXAiVri1UpqtcE6AroVFNo3RVVK6GVQOdDjZCbxYZt243dd_CogrOF9ZDvYWd8gvbVc0CdksLXx7mk88PZFRnm6huVbd8V9sTcFCqOtjTXR2D55vr-fQOzR5v76dXM2RoyjukVV6UmbAUEy1yLJQpLBe5MFqUJeb9wGjCNDc805jlosw5zxMlaCGY4oyOwcXg23r3urGhkyu38U08KRPBWELS6BqpZKCMj_97W8rWV2vlt5Jg2Ycrh3BlDFd-hytJFJ3vrDd6bYtfyU-aEaADEOKqWVj_d_sf2y9n7Ya_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2644217906</pqid></control><display><type>article</type><title>Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Vallée, Alexandre ; Lecarpentier, Yves ; Vallée, Jean-Noël</creator><creatorcontrib>Vallée, Alexandre ; Lecarpentier, Yves ; Vallée, Jean-Noël</creatorcontrib><description>Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and glutamatergic pathways play key roles in the causes of OCD. However, first-line therapies include cognitive-behavioral therapy but only 40% of the patients respond to this first-line therapy. Research for new treatment is mandatory. This review focuses on the potential effects of cannabidiol (CBD), as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which CBD provides its benefit properties. CBD medication downregulates GSK-3β, the main inhibitor of the WNT/β-catenin pathway. The activation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway and circadian rhythms dysregulation in OCD. Future prospective clinical trials could focus on CBD and its different and multiple interactions in OCD.</description><identifier>ISSN: 1359-4184</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/s41380-021-01086-1</identifier><identifier>PMID: 33837269</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/337 ; 631/80 ; 692/699/476 ; Behavioral Sciences ; beta Catenin - metabolism ; Biological Psychology ; Cannabidiol ; Cannabidiol - pharmacology ; Cannabidiol - therapeutic use ; Cannabinoids ; Circadian rhythms ; Clinical trials ; Cognitive ability ; Cognitive behavioral therapy ; Glutamatergic transmission ; Glycogen Synthase Kinase 3 beta ; Humans ; Inflammation ; Inflammation - metabolism ; Medicine ; Medicine & Public Health ; Mental disorders ; Neurosciences ; Neuroses ; Obsessive compulsive disorder ; Obsessive-Compulsive Disorder - drug therapy ; Oxidative stress ; Pharmacotherapy ; Psychiatry ; Review Article ; Wnt protein ; β-Catenin</subject><ispartof>Molecular psychiatry, 2022-01, Vol.27 (1), p.230-248</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature Limited.</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-ba9df86e301b6906acde5696cb6ff0506accb14b5c58b0496f95592a63d64a543</citedby><cites>FETCH-LOGICAL-c375t-ba9df86e301b6906acde5696cb6ff0506accb14b5c58b0496f95592a63d64a543</cites><orcidid>0000-0001-9158-4467</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41380-021-01086-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41380-021-01086-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33837269$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vallée, Alexandre</creatorcontrib><creatorcontrib>Lecarpentier, Yves</creatorcontrib><creatorcontrib>Vallée, Jean-Noël</creatorcontrib><title>Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><addtitle>Mol Psychiatry</addtitle><description>Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and glutamatergic pathways play key roles in the causes of OCD. However, first-line therapies include cognitive-behavioral therapy but only 40% of the patients respond to this first-line therapy. Research for new treatment is mandatory. This review focuses on the potential effects of cannabidiol (CBD), as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which CBD provides its benefit properties. CBD medication downregulates GSK-3β, the main inhibitor of the WNT/β-catenin pathway. The activation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway and circadian rhythms dysregulation in OCD. Future prospective clinical trials could focus on CBD and its different and multiple interactions in OCD.</description><subject>631/337</subject><subject>631/80</subject><subject>692/699/476</subject><subject>Behavioral Sciences</subject><subject>beta Catenin - metabolism</subject><subject>Biological Psychology</subject><subject>Cannabidiol</subject><subject>Cannabidiol - pharmacology</subject><subject>Cannabidiol - therapeutic use</subject><subject>Cannabinoids</subject><subject>Circadian rhythms</subject><subject>Clinical trials</subject><subject>Cognitive ability</subject><subject>Cognitive behavioral therapy</subject><subject>Glutamatergic transmission</subject><subject>Glycogen Synthase Kinase 3 beta</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation - metabolism</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mental disorders</subject><subject>Neurosciences</subject><subject>Neuroses</subject><subject>Obsessive compulsive disorder</subject><subject>Obsessive-Compulsive Disorder - drug therapy</subject><subject>Oxidative stress</subject><subject>Pharmacotherapy</subject><subject>Psychiatry</subject><subject>Review Article</subject><subject>Wnt protein</subject><subject>β-Catenin</subject><issn>1359-4184</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kE1OwzAQhS0EolC4AAtkibWpHf8kWaKKP6kCFkUsLdtx2lRpHOwU1GtxEM6EQwrsWM1o5ntvNA-AM4IvCabZJDBCM4xwQhAmOBOI7IEjwlKBOE-z_dhTniNGMjYCxyGsMO6X_BCMKM1omoj8CCyfXAiVri1UpqtcE6AroVFNo3RVVK6GVQOdDjZCbxYZt243dd_CogrOF9ZDvYWd8gvbVc0CdksLXx7mk88PZFRnm6huVbd8V9sTcFCqOtjTXR2D55vr-fQOzR5v76dXM2RoyjukVV6UmbAUEy1yLJQpLBe5MFqUJeb9wGjCNDc805jlosw5zxMlaCGY4oyOwcXg23r3urGhkyu38U08KRPBWELS6BqpZKCMj_97W8rWV2vlt5Jg2Ycrh3BlDFd-hytJFJ3vrDd6bYtfyU-aEaADEOKqWVj_d_sf2y9n7Ya_</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Vallée, Alexandre</creator><creator>Lecarpentier, Yves</creator><creator>Vallée, Jean-Noël</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><orcidid>https://orcid.org/0000-0001-9158-4467</orcidid></search><sort><creationdate>20220101</creationdate><title>Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway</title><author>Vallée, Alexandre ; Lecarpentier, Yves ; Vallée, Jean-Noël</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-ba9df86e301b6906acde5696cb6ff0506accb14b5c58b0496f95592a63d64a543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>631/337</topic><topic>631/80</topic><topic>692/699/476</topic><topic>Behavioral Sciences</topic><topic>beta Catenin - metabolism</topic><topic>Biological Psychology</topic><topic>Cannabidiol</topic><topic>Cannabidiol - pharmacology</topic><topic>Cannabidiol - therapeutic use</topic><topic>Cannabinoids</topic><topic>Circadian rhythms</topic><topic>Clinical trials</topic><topic>Cognitive ability</topic><topic>Cognitive behavioral therapy</topic><topic>Glutamatergic transmission</topic><topic>Glycogen Synthase Kinase 3 beta</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation - metabolism</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mental disorders</topic><topic>Neurosciences</topic><topic>Neuroses</topic><topic>Obsessive compulsive disorder</topic><topic>Obsessive-Compulsive Disorder - drug therapy</topic><topic>Oxidative stress</topic><topic>Pharmacotherapy</topic><topic>Psychiatry</topic><topic>Review Article</topic><topic>Wnt protein</topic><topic>β-Catenin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vallée, Alexandre</creatorcontrib><creatorcontrib>Lecarpentier, Yves</creatorcontrib><creatorcontrib>Vallée, Jean-Noël</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vallée, Alexandre</au><au>Lecarpentier, Yves</au><au>Vallée, Jean-Noël</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway</atitle><jtitle>Molecular psychiatry</jtitle><stitle>Mol Psychiatry</stitle><addtitle>Mol Psychiatry</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>27</volume><issue>1</issue><spage>230</spage><epage>248</epage><pages>230-248</pages><issn>1359-4184</issn><eissn>1476-5578</eissn><abstract>Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and glutamatergic pathways play key roles in the causes of OCD. However, first-line therapies include cognitive-behavioral therapy but only 40% of the patients respond to this first-line therapy. Research for new treatment is mandatory. This review focuses on the potential effects of cannabidiol (CBD), as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which CBD provides its benefit properties. CBD medication downregulates GSK-3β, the main inhibitor of the WNT/β-catenin pathway. The activation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway and circadian rhythms dysregulation in OCD. Future prospective clinical trials could focus on CBD and its different and multiple interactions in OCD.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33837269</pmid><doi>10.1038/s41380-021-01086-1</doi><tpages>19</tpages><orcidid>https://orcid.org/0000-0001-9158-4467</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-4184 |
| ispartof | Molecular psychiatry, 2022-01, Vol.27 (1), p.230-248 |
| issn | 1359-4184 1476-5578 |
| language | eng |
| recordid | cdi_proquest_journals_2644217906 |
| source | MEDLINE; SpringerLink Journals |
| subjects | 631/337 631/80 692/699/476 Behavioral Sciences beta Catenin - metabolism Biological Psychology Cannabidiol Cannabidiol - pharmacology Cannabidiol - therapeutic use Cannabinoids Circadian rhythms Clinical trials Cognitive ability Cognitive behavioral therapy Glutamatergic transmission Glycogen Synthase Kinase 3 beta Humans Inflammation Inflammation - metabolism Medicine Medicine & Public Health Mental disorders Neurosciences Neuroses Obsessive compulsive disorder Obsessive-Compulsive Disorder - drug therapy Oxidative stress Pharmacotherapy Psychiatry Review Article Wnt protein β-Catenin |
| title | Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T05%3A47%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Possible%20actions%20of%20cannabidiol%20in%20obsessive-compulsive%20disorder%20by%20targeting%20the%20WNT/%CE%B2-catenin%20pathway&rft.jtitle=Molecular%20psychiatry&rft.au=Vall%C3%A9e,%20Alexandre&rft.date=2022-01-01&rft.volume=27&rft.issue=1&rft.spage=230&rft.epage=248&rft.pages=230-248&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/s41380-021-01086-1&rft_dat=%3Cproquest_cross%3E2644217906%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2644217906&rft_id=info:pmid/33837269&rfr_iscdi=true |